drugset
drugset / Trial / NCT00986284

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

NCT00986284 ↗

Phase 2 Suspended 102 enrolled Tianjin Medical University Cancer Institute and Hospital
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.

Timeline

Start
2009-09
Primary completion
2016-11
Completion
2016-11

Outcome

Outcome not reported

Stopped: “Lack of patients and some progressed disease soon after surgery”

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule — —

Indications

non-small cell lung carcinoma